• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2019冠状病毒病急性肾损伤的发病率、危险因素及预后的前瞻性研究

A Prospective Study of Incidence, Risk Factors, and Outcomes of Acute Kidney Injury in Coronavirus Disease 2019.

作者信息

Bansal Shyam Bihari, Babras Mayur, Rana Abhyudaysingh, Mahapatra Amit, Yadav Dinesh Kumar, Sethi Sidharth Kumar

机构信息

Department of Nephrology and Kidney Transplantation, Medanta Kidney and Urology Institute, Medanta-The Medicity, Gurgaon, Haryana, India.

Department of Nephrology, Seth Nandlal, Dhoot Hospital, Aurangabad, Maharashtra, India.

出版信息

Indian J Nephrol. 2024 Sep-Oct;34(5):461-466. doi: 10.25259/ijn_399_23. Epub 2024 May 11.

DOI:10.25259/ijn_399_23
PMID:39372632
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11450852/
Abstract

BACKGROUND

Acute kidney injury (AKI) is common after coronavirus 2 infection (COVID-19), leading to higher morbidity and mortality. There is little prospective data from India regarding the incidence, risk factors, and outcome of AKI in COVID-19.

MATERIALS AND METHODS

This study was conducted prospectively in adult patients between September and December 2020 in a tertiary care hospital in the national capital region of Delhi. A total of 856 patients with COVID-19 infection were enrolled in the study. Survivors were followed for 3 months after discharge.

RESULTS

Out of 856 patients, 207 (24%) developed AKI. AKI was significantly higher in those with severe disease as compared to mild-moderate disease (88% vs. 12%, = 0.04). Out of all AKI, 3.4% had stage 1, 9.2% had stage 2, and the rest 87.4% had stage 3 AKI. 183/207 (88%) patients were on mechanical ventilators, 133 (64%) required inotropic support, and 137/207 (83.6%) patients required kidney replacement therapy. Out of 207 AKI patients, 74% (153) died as compared to 4% (27) in non-AKI group ( = 0.0001). After 3 months, chronic kidney disease (CKD) developed in 10/54 (18.5%) patients. On multivariable analysis, the presence of diabetes mellitus, severe COVID-19 disease, high levels of C reactive protein, lactate dehydrogenase, D-Dimer, and use of intravenous steroids, tocilizumab and remdesivir, were found to be significant predictors of AKI.

CONCLUSION

AKI is common after COVID-19 infection and it is a significant risk factor for mortality in COVID-19. Patients with diabetes and high levels of inflammatory markers have higher mortality. CKD may develop in many patients after discharge.

摘要

背景

新型冠状病毒2感染(COVID-19)后急性肾损伤(AKI)很常见,会导致更高的发病率和死亡率。在印度,关于COVID-19中AKI的发病率、危险因素和结局的前瞻性数据很少。

材料与方法

本研究于2020年9月至12月在德里国家首都地区的一家三级护理医院对成年患者进行前瞻性研究。共有856例COVID-19感染患者纳入研究。幸存者出院后随访3个月。

结果

856例患者中,207例(24%)发生AKI。与轻中度疾病患者相比,重症患者的AKI发生率显著更高(88%对12%,P = 0.04)。在所有AKI患者中,3.4%为1期,9.2%为2期,其余87.4%为3期AKI。207例患者中有183例(88%)使用机械通气,133例(64%)需要使用血管活性药物支持,137例(83.6%)患者需要肾脏替代治疗。207例AKI患者中,74%(153例)死亡,而非AKI组为4%(27例)(P = 0.0001)。3个月后,54例患者中有10例(18.5%)发生慢性肾脏病(CKD)。多变量分析显示,糖尿病、重症COVID-19疾病、高C反应蛋白、乳酸脱氢酶、D-二聚体水平以及使用静脉类固醇、托珠单抗和瑞德西韦是AKI的显著预测因素。

结论

COVID-19感染后AKI很常见,且是COVID-19患者死亡的重要危险因素。糖尿病患者和炎症标志物水平高的患者死亡率更高。许多患者出院后可能会发生CKD。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b605/11450852/2df0a8e0bfe8/IJN-34-5-461-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b605/11450852/2df0a8e0bfe8/IJN-34-5-461-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b605/11450852/2df0a8e0bfe8/IJN-34-5-461-g1.jpg

相似文献

1
A Prospective Study of Incidence, Risk Factors, and Outcomes of Acute Kidney Injury in Coronavirus Disease 2019.2019冠状病毒病急性肾损伤的发病率、危险因素及预后的前瞻性研究
Indian J Nephrol. 2024 Sep-Oct;34(5):461-466. doi: 10.25259/ijn_399_23. Epub 2024 May 11.
2
Incidence, Risk Factors and Outcome of COVID-19 Associated AKI- A Study from South India.印度南部地区 COVID-19 相关急性肾损伤的发病率、危险因素和转归研究
J Assoc Physicians India. 2021 Jun;69(6):11-12.
3
Clinical profile and outcomes of COVID-19 patients with acute kidney injury: a tertiary centre experience from South India.印度南部一家三级医院的 COVID-19 合并急性肾损伤患者的临床特征和转归。
Clin Exp Nephrol. 2022 Jan;26(1):36-44. doi: 10.1007/s10157-021-02123-7. Epub 2021 Aug 16.
4
Clinical characteristics and outcome of critically ill COVID-19 patients with acute kidney injury: a single centre cohort study.COVID-19 危重症患者合并急性肾损伤的临床特征和转归:一项单中心队列研究。
BMC Nephrol. 2021 Mar 15;22(1):92. doi: 10.1186/s12882-021-02296-z.
5
Acute Kidney Injury in COVID-19: Clinical Profile and Outcome.新型冠状病毒肺炎相关急性肾损伤:临床特征与预后
Indian J Nephrol. 2022 Jul-Aug;32(4):291-298. doi: 10.4103/ijn.IJN_21_21. Epub 2022 May 7.
6
Spectrum, Outcomes, and Mortality Predictors of Acute Kidney Injury among Non-COVID-19 Patients during COVID-19 Pandemic: Data from Four Intensive Care Units.新冠疫情期间非新冠患者急性肾损伤的谱、结局及死亡率预测因素:来自四个重症监护病房的数据
Indian J Crit Care Med. 2023 Feb;27(2):119-126. doi: 10.5005/jp-journals-10071-24408.
7
The Risk Factors and Clinical Outcomes Associated with Acute Kidney Injury in Patients with COVID-19: Data from a Large Cohort in Iran.与 COVID-19 患者急性肾损伤相关的危险因素和临床结局:来自伊朗大型队列的数据。
Kidney Blood Press Res. 2021;46(5):620-628. doi: 10.1159/000517581. Epub 2021 Jul 27.
8
Acute kidney injury prevalence, progression and long-term outcomes in critically ill patients with COVID-19: a cohort study.新型冠状病毒肺炎危重症患者急性肾损伤的患病率、进展及长期预后:一项队列研究
Ann Intensive Care. 2021 Aug 6;11(1):123. doi: 10.1186/s13613-021-00914-5.
9
Profile of Acute Kidney Injury in the Pediatric Age Group in a Tertiary Care Hospital: A Prospective Observational Study.三级护理医院儿科急性肾损伤概况:一项前瞻性观察研究
Cureus. 2024 Feb 15;16(2):e54236. doi: 10.7759/cureus.54236. eCollection 2024 Feb.
10
Characteristics and outcomes of acute kidney injury in hospitalized COVID-19 patients: A multicenter study by the Turkish society of nephrology.土耳其肾脏病学会多中心研究:住院 COVID-19 患者急性肾损伤的特征和结局。
PLoS One. 2021 Aug 10;16(8):e0256023. doi: 10.1371/journal.pone.0256023. eCollection 2021.

引用本文的文献

1
Author's Reply.作者回复。
Indian J Nephrol. 2025 Jul-Aug;35(4):578-579. doi: 10.25259/IJN_782_2024. Epub 2025 Feb 25.
2
COVID-19 and a Tale of Three Drugs: To Repurpose, or Not to Repurpose-That Was the Question.新冠疫情与三种药物的故事:是否进行药物再利用——这就是问题所在。
Viruses. 2025 Jun 23;17(7):881. doi: 10.3390/v17070881.
3
Evaluating the Impact of Therapeutic Anticoagulation on Acute Kidney Injury in COVID-19: Insights and Future Directions.评估治疗性抗凝对新型冠状病毒肺炎急性肾损伤的影响:见解与未来方向

本文引用的文献

1
Characteristics and outcomes of acute kidney injury in hospitalized COVID-19 patients: A multicenter study by the Turkish society of nephrology.土耳其肾脏病学会多中心研究:住院 COVID-19 患者急性肾损伤的特征和结局。
PLoS One. 2021 Aug 10;16(8):e0256023. doi: 10.1371/journal.pone.0256023. eCollection 2021.
2
Acute kidney injury prevalence, progression and long-term outcomes in critically ill patients with COVID-19: a cohort study.新型冠状病毒肺炎危重症患者急性肾损伤的患病率、进展及长期预后:一项队列研究
Ann Intensive Care. 2021 Aug 6;11(1):123. doi: 10.1186/s13613-021-00914-5.
3
Acute kidney injury, a common and severe complication in hospitalized patients during the COVID-19 pandemic.
Indian J Nephrol. 2025 May-Jun;35(3):447-448. doi: 10.25259/IJN_716_2024. Epub 2024 Dec 26.
在 COVID-19 大流行期间,急性肾损伤是住院患者中常见且严重的并发症。
J Nephrol. 2021 Aug;34(4):1019-1024. doi: 10.1007/s40620-021-01087-x. Epub 2021 Jun 19.
4
Differences between First wave and Second wave of COVID-19 in India.印度新冠疫情第一波和第二波之间的差异。
Diabetes Metab Syndr. 2021 May-Jun;15(3):1047-1048. doi: 10.1016/j.dsx.2021.05.009. Epub 2021 May 8.
5
Chest CT Severity Score: An Imaging Tool for Assessing Severe COVID-19.胸部CT严重程度评分:一种评估重症COVID-19的影像学工具。
Radiol Cardiothorac Imaging. 2020 Mar 30;2(2):e200047. doi: 10.1148/ryct.2020200047. eCollection 2020 Apr.
6
The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong?COVID-19 发病机制中的促炎细胞因子:出了什么问题?
Microb Pathog. 2021 Apr;153:104799. doi: 10.1016/j.micpath.2021.104799. Epub 2021 Feb 18.
7
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.托珠单抗对重症或危重症 2019 冠状病毒病患者 15 天临床结局的影响:随机对照试验。
BMJ. 2021 Jan 20;372:n84. doi: 10.1136/bmj.n84.
8
Use of Remdesivir in Patients With COVID-19 on Hemodialysis: A Study of Safety and Tolerance.瑞德西韦在接受血液透析的COVID-19患者中的应用:安全性和耐受性研究。
Kidney Int Rep. 2021 Mar;6(3):586-593. doi: 10.1016/j.ekir.2020.12.003. Epub 2020 Dec 18.
9
Epidemiology and Outcomes of Acute Kidney Injury in COVID-19 Patients with Acute Respiratory Distress Syndrome: A Multicenter Retrospective Study.新型冠状病毒肺炎合并急性呼吸窘迫综合征患者急性肾损伤的流行病学和结局:一项多中心回顾性研究。
Blood Purif. 2021;50(4-5):499-505. doi: 10.1159/000512371. Epub 2020 Dec 8.
10
Role of favipiravir in the treatment of COVID-19.法匹拉韦在治疗 COVID-19 中的作用。
Int J Infect Dis. 2021 Jan;102:501-508. doi: 10.1016/j.ijid.2020.10.069. Epub 2020 Oct 30.